hydroxyoctadecadienoic-acid and Epilepsy

hydroxyoctadecadienoic-acid has been researched along with Epilepsy* in 1 studies

Other Studies

1 other study(ies) available for hydroxyoctadecadienoic-acid and Epilepsy

ArticleYear
Dynamics of hydroxyoctadecadienoic acid in epilepsy patients treated with valproic acid.
    Pediatrics international : official journal of the Japan Pediatric Society, 2016, Volume: 58, Issue:1

    The effects of valproic acid (VPA) on oxidative stress are controversial due to differences in experimental conditions. Recently, total hydroxyoctadecadienoic acid (tHODE), derived from linoleic acid, was proposed as a potent biomarker to evaluate oxidative stress.. The subjects consisted of 10 new-onset epilepsy patients treated with VPA. We measured plasma tHODE consecutively for 1 year to evaluate the degree of oxidative stress and then compared plasma tHODE at the beginning and the end of experiments with the peak level. Ten age-matched healthy subjects were recruited as a control group and their plasma tHODE was compared to the initial plasma tHODE of the epilepsy group. Measurements were done using liquid chromatography-tandem mass spectrometry.. Mean initial plasma tHODE in the epilepsy group was 165.2 ± 76.8 nmol/L, which was not significantly different from that of the control group (199.3 ± 62.5 nmol/L). In five epilepsy patients, plasma tHODE increased above the pathological level in 6 months, but returned to normal within 1 year. In the whole group, the difference plasma tHODE between peak, at the beginning and 1 year later, was significant.. Oxidative stress generated by VPA increased temporarily, but decreased to normal after 1 year. it is reasonable to be concerned about the effects of oxidative stress, especially at the start of VPA treatment.

    Topics: Adolescent; Anticonvulsants; Biomarkers; Child; Child, Preschool; Epilepsy; Fatty Acids, Unsaturated; Female; Humans; Male; Oxidative Stress; Retrospective Studies; Valproic Acid

2016